Company profile for Glycostem Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Glycostem Therapeutics is focused on the development of stem cell-derived Natural Killer cells (NK-cells) as a medicinal asset in the fight against cancer. NK-cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing” of cancer cells; they play an important role in control and even cure of both solid and hematological malignancies, like Acute Myeloid Leukemia (AML) and ...
Glycostem Therapeutics is focused on the development of stem cell-derived Natural Killer cells (NK-cells) as a medicinal asset in the fight against cancer. NK-cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing” of cancer cells; they play an important role in control and even cure of both solid and hematological malignancies, like Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM).

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Netherlands
Address
Address
Kloosterstraat 9 5349 AB Oss The Netherlands
Telephone
Telephone
+31-(0) 412 211 001
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/glycostem-and-medac-enter-into-license-manufacturing-supply-and-commercialization-agreement-for-glycostems-lead-product---onkord-301596859.html

PRNEWSWIRE
01 Aug 2022

https://www.prnewswire.com/news-releases/glycostem-announces-new-data-presentation-at-eha-2022-congress-highlighting-early-safety-and-clinical-course-of-onkord-in-patients-with-acute-myeloid-leukemia-301546878.html

PRNEWSWIRE
13 May 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty